FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96

March 8-11, 2020; Boston, Massachusetts
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: March 11, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Dr William R. Short: key considerations for deciding whether to continue bictegravir in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings